Catalyst
Slingshot members are tracking this event:
AstraZeneca's Lynparza (olaparib) phase 3 SOLO-2 trial shows survival benefit in BRCA-Mutated Ovarian Cancer
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| AZN |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Mar 14, 2017
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase 3, Lynparza, Olaparib, Solo-2, Brca-related Ovarian Cancer
